Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-28T02:26:36.091Z Has data issue: false hasContentIssue false

Ifosfamide Encephalopathy and Nonconvulsive Status Epilepticus

Published online by Cambridge University Press:  14 September 2018

Alberto Primavera
Affiliation:
Department of Neurological Sciences and Vision, University of Genova, Genova, Italy
Daniela Audenino
Affiliation:
Department of Neurological Sciences and Vision, University of Genova, Genova, Italy
Leonardo Cocito*
Affiliation:
Department of Neurological Sciences and Vision, University of Genova, Genova, Italy
*
Leonardo Cocito, Dipartimento di Scienze Neurologiche e della Visione, Via De Toni 5, I-16132 Genova, Italy.
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Ifosfamide (IFX), an alkylating agent and isomer of cyclophosphamide, is used as a single agent or a component of multi-agent chemotherapy in the treatment of ovarian, testicular, head and neck cancers, sarcomas and lymphomas. Encephalopathy is manifested by cerebellar ataxia, confusional state, complex visual hallucinations, extrapyramidal signs, seizures, and mutism.

Case reports:

We report two patients with non-Hodgkin’s lymphoma presenting with mutism and confusional state after IFX infusion. Nonconvulsive status epilepticus (NCSE) as the cause of confusion was diagnosed on the basis of EEG pattern and the apparent improvement following intravenous administration of diazepam.

Conclusions:

Electroencephalogram abnormalities during IFX treatment have been described but recordings are only available in six cases. In three of them, paroxysmal alterations warranted the diagnosis of NCSE; however, most cases of IFX encephalopathy might have associated NCSE.

Résumé:

Résumé:Introduction:

L’ifosfamide (IFX), un agent alkylant isomère de la cyclophosphamide, est utilisé en monothérapie ou en thérapie combinée en chimiothérapie du cancer de l’ovaire, du testicule, de la tête et du cou, de sarcomes et de lymphomes. L’encéphalopathie se manifeste par une ataxie cérébelleuse, un état confusionnel, des hallucinations visuelles complexes, des signes extrapyramidaux, des crises convulsives et du mutisme.

Observation:

Nous rapportons le cas de deux patients atteints de lymphomes non hodgkiniens, qui ont présenté du mutisme et un état confusionnel après une infusion de IFX. Le diagnostic de status epilepticus non convulsif (SÉNC) comme étiologie de la confusion a été posé en se basant sur le tracé ÉEG et l’amélioration suite à l’administration intraveineuse de diazépam.

Conclusions:

Des anomalies ÉEG pendant le traitement à l’IFX ont été décrites, mais les tracés ne sont disponibles que dans six cas. Dans trois de ces cas, des altérations paroxystiques ont justifié le diagnostic de SÉNC. Cependant, la plupart des cas d’encéphalopathie à l’IFX pourraient être associés à un SÉNC.

Type
Case Reports
Copyright
Copyright © Canadian Neurological Sciences Federation 2002

References

1. Hammack, JE, Cascino, TL. Chemotherapy and other common druginduced toxicities of the central nervous system in patients with cancer. In: Vecht, ChJ, ed. Handbook of Clinical Neurology, Vol. 25(69): Neuro-Oncology, Part III. Amsterdam: Elsevier Science B.V., 1997: 481-493.Google Scholar
2. Meanwell, CA, Blake, AE, Blackledge, G, et al. Encephalopathy associated with ifosfamide/mesna therapy. Lancet 1985; 1: 406-407.CrossRefGoogle Scholar
3. Meanwell, CA, Blake, AE, Kelly, KA, Honigsberger, L, Blackledge, G. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986; 22: 815-819.CrossRefGoogle Scholar
4. Gieron, A, Barak, LS, Estrada, J. Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors. J Neurooncol 1988; 6: 29-30.Google Scholar
5. Wengs, WJ, Talwar, D, Bernard, J. Ifosfamide-induced nonconvulsive status epilepticus. Arch Neurol 1993; 50: 1104-1105.Google Scholar
6. Bhardwaj, A, Badesha, PS. Ifosfamide-induced nonconvulsive status epilepticus. Ann Pharmacother 1995; 29: 1237-1239.CrossRefGoogle Scholar
7. Kaplan, PW. Nonconvulsive status epilepticus in the emergency room. Epilepsia 1996; 37: 643-650.CrossRefGoogle Scholar
8. Adde, M, Shad, A, Venzon, D, et al. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol 1998; 25: 33-39.Google Scholar
9. Simonian, NA, Gilliam, FG, Chiappa, KH. Ifosfamide causes a diazepam-sensitive encephalopathy. Neurology 1993: 43: 2700-2702.CrossRefGoogle Scholar
10. Homeida, AM, Cooke, RG. Anti-convulsant activity of diazepam and clonidine on metaldehyde-induced seizures in mice: effects on brain gamma-amino butyric acid concentrations and monoamine oxidase activity. J Vet Pharmacol Ther 1982; 5: 187-190 CrossRefGoogle Scholar
11. Kupfer, A, Aeschlimann, C, Wermuth, B, Cerny, T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994; 343: 763-764.CrossRefGoogle Scholar
12. Danesh, MM, De Giorgio, CM, Beydoun, SR, Kemp, RA. Ifosfamide encephalopathy. J Toxicol Clin Toxicol 1989; 27: 293-298.CrossRefGoogle Scholar
13. Guberman, A, Cantu-Reyna, G, Stuss, D, Broughton, R. Nonconvulsive generalized status epilepticus: clinical features, neuropsychological testing, and long-term follow-up. Neurology 1986; 36: 1284-1291.CrossRefGoogle Scholar
14. Litt, B, Wityk, RJ, Hertz, SH, et al. Nonconvulsive status epilepticus in the critically ill elderly. Epilepsia 1998; 39: 1194-1202.Google Scholar
15. Ghosn, M, Carde, P, Leclerq, B, et al. Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity. Bull Cancer 1988; 75: 391-392.Google Scholar
16. Young, GB, Jordan, KG, Doig, GS. An assessment of nonconvulsive seizures in the intensive care unit using continuous EEG monitoring. An investigation of variables associated with mortality. Neurology 1996; 47: 83-89.Google Scholar